Malignant Germ Cell Tumor Management in Ovarian Oncology
Summary
Malignant ovarian germ cell tumours represent a rare subset of ovarian neoplasms that primarily affect children, adolescents and young adults. Characterised by diverse histological subtypes—most notably dysgerminoma, immature teratoma and yolk sac tumour—these malignancies exhibit high chemosensitivity and generally favourable prognoses when managed optimally. The cornerstone of treatment is fertility-sparing surgery for early-stage disease, aiming to remove the tumour while preserving reproductive potential. Adjuvant chemotherapy, most commonly platinum-based regimens such as bleomycin, etoposide and cisplatin, is indicated for higher-grade or advanced-stage cases to eradicate micrometastatic disease. Recent advances emphasise risk-adapted approaches: tumour stage, histological grade and serum biomarkers guide the intensity and duration of systemic therapy. Multidisciplinary collaboration across gynaecologic oncology, paediatric oncology and reproductive medicine has fostered international consensus on harmonised protocols. Ongoing challenges include minimising long-term toxicities, addressing cisplatin-resistant recurrences and refining strategies for rare variants. Nonetheless, the integration of conservative surgery, tailored chemotherapy and survivorship care has markedly improved both oncological and functional outcomes, underscoring the importance of personalised management in this unique patient population.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Malignant Germ Cell Tumor Management in Ovarian Oncology publication trend
The graph below shows the total number of articles in malignant germ cell tumor management in ovarian oncology across all publications each year (not limited to Nature Index journals).
Technical terms
Germ cell tumour: A neoplasm arising from primordial germ cells, often with rapid growth and high responsiveness to chemotherapy.
Dysgerminoma: The most common malignant germ cell tumour of the ovary, notable for its uniform cells and excellent platinum sensitivity.
Immature teratoma: A malignant ovarian tumour containing embryonic tissue elements, graded by the proportion of immature neuroepithelial components.
Adjuvant chemotherapy: Systemic treatment given after surgical resection to eliminate residual microscopic disease and reduce recurrence risk.
Fertility-sparing surgery: Surgical technique preserving the uterus and at least one ovary to maintain future reproductive function.
Cisplatin resistance: The phenomenon whereby tumour cells exhibit reduced sensitivity to cisplatin, necessitating alternative therapeutic strategies.
References
- Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine (2024).
- A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. European Journal of Cancer (2019).
- Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery. Biomedicines (2020).
- Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. Cancers (2019).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.